Taysha Gene Therapies Inc

NASDAQ:TSHA   4:00:00 PM EDT
2.18
-0.11 (-4.80%)
7:31:14 PM EDT: $2.20 +0.02 (+0.92%)
Earnings Announcements

Taysha Gene Therapies Reports Third Quarter Financial Results

Published: 11/08/2022 12:37 GMT
Taysha Gene Therapies Inc (TSHA) - Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update.
Taysha - $50 Million Strategic Investment From Astellas Pharma to Support Development of Tsha-120 in Giant Axonal Neuropathy,tsha-102 in Rett Syndrome.
Taysha Gene Therapies Inc - As of September 30, 2022, Company Had Cash and Cash Equivalents of $34.3 Million.
Taysha Gene Therapies - Expects Existing Cash and Cash Equivalents, Receipt of Other Payments to Enable Cash Runway Into Q1 2024.
Revenue is expected to be $10 Million
Adjusted EPS is expected to be -$0.36

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.54

More details on our Analysts Page.